(NEW YORK) Katten Muchin Rosenman LLP announced today the addition of Deepro R. Mukerjee and Lance Soderstrom as partners in its Intellectual Property (IP) practice group in New York and Dr. Jitendra "Jitty" Malik as a partner in the IP group in Charlotte.
"Our IP practice attorneys represent some of the world's most recognized companies in a range of litigations in which we are called upon to protect our clients' most valuable intellectual property," said Katten Chairman Roger P. Furey. "Deepro, Jitty and Lance all have first-rate legal and technical skills and are held in the highest regard by the clients they have assisted for many years. This will expand our industry-leading capabilities allowing us to offer superior IP representation across the globe."
A nationally recognized leader and trial attorney in the patent arena, Mukerjee, over the course of nearly 20 years, has been lead trial counsel for some of the world's largest pharmaceutical and biotech companies. He is particularly experienced in complex pharmaceutical litigation brought under the Hatch-Waxman Act and is known nationally for his Abbreviated New Drug Application (ANDA) work, often taking such matters to trial and subsequent appeal. Outside the ANDA world, Mukerjee has litigated intellectual property rights in a wide range of technologies, from biotechnology processes to electrical circuit-interrupting devices and computer software programs.
Dr. Malik holds a PhD in Polymer Science and Engineering and has substantial experience in the drug approval process under the Hatch-Waxman Act. He also has extensive experience in post grant proceedings involving pharmaceutical patents including inter partes reviews, ex parte re-examinations and reissue proceedings. His practice includes developing patent strategies that assist clients in marketing drug products and evaluating competitive patents. Using his extensive knowledge of chemistry, biochemistry, physics and electrochemistry, Dr. Malik focuses his practice on patent litigation, opinions, IP due diligence, licensing and prosecution in many areas.
Soderstrom, who has worked closely with Mukerjee, has litigated patents relating to a range of technologies, from pharmaceutical compounds and formulations to medical devices and computer software programs, in district courts throughout the country. He has particular experience in the drug approval process under the Hatch-Waxman Act, including the development of patent strategies to assist clients in marketing drug products and evaluating competitive patents.
Mukerjee, Dr. Malik and Soderstrom all join Katten from Alston & Bird LLP.
"While our attorneys have litigated virtually every type of patent infringement case, significant parts of our practice involve pharmaceutical patents," said Brian Sodikoff, national head of Katten's Patent Litigation group. "We are a team committed to achieving the best results possible in contested matters, whether through litigation, mediation, arbitration or settlement. In this way, Deepro, Jitty and Lance are a great fit for our group. We look forward to working with them."
